Original vs generic drugs in treatment of chronic myeloid leukaemia

Journal Title: OncoReview - Year 2014, Vol 4, Issue 3

Abstract

The beginning of the twenty-first century saw a breakthrough in haematology, oncology and general medicine driven by the introduction of imatinib (Glivec) to the treatment of chronic myeloid leukaemia. For the first time, a neoplastic disease was successfully treated by a therapy targeting the genetic cause of the disease. At present, targeted therapy based on imatinib is the first one to enter a new stage which is the launch of generic drugs. Poland is the first country in the European Union which, from the beginning of July 2014, introduced generic imatinib. Hence, there is no reliable data on its use except for results from bioequivalence tests. The only data available comes from developing countries where other preparations are used, without reliable bioequivalence studies. However, all generic drugs of imatinib registered in Poland have successfully passed such tests. Undoubtedly, it is necessary to appropriately monitor patients with chronic myeloid leukaemia receiving generic drugs in order to ensure their safety and provide information to other countries where therapy based on generic drugs will be introduced in the following years.

Authors and Affiliations

Patrycja Rusicka

Keywords

Related Articles

Angioplastyka wieńcowa oraz wymiana zastawki aortalnej u dwóch chorych ze szpiczakiem mnogim - opisy przypadków

Szpiczak mnogi jest schorzeniem hematologicznym charakteryzującym się klonalnym rozrostem atypowych plazmocytów, produkujących monoklonalną immunoglobulinę. Roczna zapadalność na niego w Europie wynosi ok. 4,5/100 000 os...

Diagnostyka i leczenie akromegalii

Akromegalia jest chorobą przewlekłą, wywołaną nadmiernym wydzielaniem hormonu wzrostu i wtórnie podwyższonym stężeniem insulinopodobnego czynnika wzrostu 1 (IGF-1). Nieleczona lub nieprawidłowo leczona choroba skutkuje r...

Hope

In our next article we would like to draw your attention to issue of hope. Taking into account our experience with one of our patient our goal is to establish what hope means for a person in the terminal phase of cancer....

Report from the ESMO Conference on Sarcoma and GIST, 9–10 March 2012, Milan, Italy

In 9–10 March 2012, Milan (Italy), the conference organized by the European Society for Medical Oncology (ESMO) took place. The main topic of the conference was sarcomas and gastrointestinal stromal tumors (GIST). This c...

Nowa klasyfikacja NET

Zagadnienia związane z diagnostyką i kliniką nowotworów neuroendokrynnych przewodu pokarmowego dotyczą trzech kierunków działania. Pierwszym z nich jest zbieranie danych w ramach rejestrów gromadzących dane z różnych ośr...

Download PDF file
  • EP ID EP67764
  • DOI -
  • Views 195
  • Downloads 0

How To Cite

Patrycja Rusicka (2014). Original vs generic drugs in treatment of chronic myeloid leukaemia. OncoReview, 4(3), 126-131. https://europub.co.uk./articles/-A-67764